RESTORATION OF HEARING LOSS

• US 20110086002A1
• Filed: 06/19/2007
• Published: 04/14/2011
• Est. Priority Date: 06/22/2006
• Status: Active Grant

• Current Assignee: Tai June Yoo
• Original Assignee: Tai June Yoo
• Inventors: Yoo, Tai June
• Granted Patent: US 8,227,437 B2
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 38/191 Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
• CPC Class Codes: A61K 38/20 Interleukins [IL]
• CPC Class Codes: A61K 38/2026 IL-4
• CPC Class Codes: A61K 38/208 IL-12
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61K 38/45 Transferases (2)
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: C12N 2799/027 where the vector is derived from a retrovirus
• CPC Class Codes: C12N 2799/06 in vitro

Abstract

The present invention relates to compositions and methods for restoring hearing loss. In particular aspects, the invention relates to the administration of compositions that encode an inflammatory response control element. The compositions are prepared and administered in such a manner that the inflammatory response control element coding sequence is expressed in the subject to which the composition is administered. The compositions include expression systems, delivery systems, and certain inflammatory response control genes.

Claims

1-246. -246. (canceled)

247. A method of treating or ameliorating hearing loss, said method comprising administering a composition comprising nucleic acid that reduces inflammation,

wherein said nucleic acid comprises a sequence encoding one or more polypeptides selected from the group consisting of IL-12p40, IL-4, IL-10, TGFβ

, anti-TNFα

-scFv, IL-5, IL-13, type II collagen, cyanogen bromide peptide 11 (CB11) of type II collagen, cyanogen bromide peptide 9 (CB9) of type II collage, type IX collagen, c-raf protein, P0 protein, P30 protein, β

-tubulin, and cochlin or fragments thereof.

248. The method of claim 247, wherein said nucleic acid comprises one or more selected from the group consisting of a polynucleotide, DNA, RNA, antisense nucleic acid, and siRNA.

249. The method of claim 247, wherein said polynucleotide is a plasmid comprising a promoter/enhancer transcriptionally linked to said sequence encoding an inflammatory response control polypeptide.

250. The method of claim 247, wherein said nucleic acid is administered with a transfection facilitating material.

251. The method of claim 247, wherein said administering comprises one or more methods selected from the group consisting of intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, inhalation, and gene gun.

252. The method of claim 247, wherein said hearing loss is caused by an autoimmune disease.

253. The method of claim 252, wherein said autoimmune disease is an autoimmune inner ear disease.

254. The method of claim 253, wherein said autoimmune inner ear disease is Meiners disease.

255. The method of claim 253, wherein said autoimmune inner ear disease is induced by antigens comprising one or more antigens selected from the group consisting of type II collagen, type IX collagen, c-raf protein, P0 protein, P30 protein, cochlin, and β

-tubulin.

256. The method of claims 247, wherein said administering increases expression of a gene that decreases inflammation.

257. The method of claim 247, wherein, said administering inhibits or attenuates expression of a gene that increases inflammation.

258. The method of claim 247, wherein said one fragment comprises at least 25 amino acids homologous to said one or more polynucleotides.

259. The method of claim 247, wherein said nucleic acid comprises a contiguous segment of at least 50 nucleotides that are homologous to a sequence encoding said one or more polypeptides.

260. The method of claim 247, wherein said one or more polypeptides comprises one or more sequences selected from SEQ ID NOs:

16-29 or fragment thereof.

261. The method of claim 247, wherein said nucleic acid comprises one or more sequences selected from SEQ ID NOs:

1-15 or fragment thereof.

262. The method of claim 260, wherein said one fragment comprises at least 25 amino acids homologous to said one or more polynucleotides.

263. The method of claim 261, wherein said nucleic acid comprises a contiguous segment of at least 50 nucleotides that are homologous to a sequence encoding said one or more polypeptides.